We recently advised our client Medicover in concluding a strategic agreement with NIPD Genetics under which the two companies will cooperate to provide NIPD Genetics' VERACITY and VERAGENE non-invasive prenatal examinations to the Medicover network and other new markets and to design and develop new genetic tests in the prenatal, postnatal, neonatal, oncological and other fields, jointly offering a comprehensive portfolio of advanced diagnostics.
Medicover is a leading international healthcare and diagnostic services company with operations in Poland, Germany, Romania, Ukraine and other markets in Western Europe, Central and Eastern Europe and other emerging markets. It offers a broad range of high quality healthcare services and a significant hub-and-spoke diagnostic laboratory network, all underpinned by a sophisticated proprietary IT infrastructure. In 2017, Medicover had revenue of around € 580 million and 15,900 employees.
NIPD Genetics is an innovative biotechnology company based in Cyprus and is active in the design, development and manufacture of non-invasive genetic tests. NIPD Genetics was established in 2011 and offers in-vitro diagnostic solutions and non-invasive prenatal screening.
The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.
We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.